title: Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
abstract: Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.
authors.affiliation: Clinic and Policlinic of Pneumology, Inselspital, Switzerland.
authors.forename: Florian
authors.initials: F
authors.lastname: Barth
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Gerber
authors.forename: Jürg
authors.initials: J
authors.lastname: Reichen
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dufour
authors.forename: Laurent P
authors.initials: LP
authors.lastname: Nicod
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D051437:Renal Insufficiency / Q000150:complications; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan